Atypical antipsychotics in the elderly;Atypische antipsychotica bij ouderen

Tijdschrift voor Gerontologie en Geriatrie

Volumn 35, Issue 6, 2004, Pages 240-245

  Van Melick, E J M ^a   Van Der Cammen, T J M ^b   Groen, S P C ^b   Jansen, P A F ^b   Jansen, R W M M ^b   Knol, W ^b   Mannesse, C K ^b   Van Marum, R J ^b   De Smet, P A G M ^b   Scholzel Dorenbos C J M ^b   Vingerhoets, R W ^b   De Vries, O ^b  

^a The Netherlands   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGED; AGGRESSION; ARTICLE; DEMENTIA; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; GERIATRIC DISORDER; GERONTOPSYCHIATRY; HUMAN; MOTOR PERFORMANCE; PARKINSON DISEASE; PSYCHOSIS; RECEPTOR OCCUPANCY; TARDIVE DYSKINESIA;

AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; TREATMENT OUTCOME;

EID: 19944431068     PISSN: 01679228     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonine2 pKi values. J Pharmacol Experiment Therapeutics 1989; 251: 238-51.
2. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996; 57 suppl 11: 4-11.
3. Leysen JE, Janssen PMF, Heylen L, Gommeren W, van Gompel P, Lesage AS, et al.. Receptor interactions of new antipsychotics: relation to pharmacodynamic and clincal effects. Int J Psychiatry in Clin Practice 1998; 2: S3-S17.
4. Kapur S, Zipursky R, Jones C, remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response and side effects: a double blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514-20.
5. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999; 156: 876-84.
6. Kapur s, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158: 360-69.
7. Kapur S, McClelland RA, VanderSpek SC, Wadenberg MG, Baker G, Nobrega J et al. Increasing D2 affinity results in the loss of clozapine' satypical antipsychotic action. Cogn Neuroscience Neuropsychol 2002; 13: 831-35.
8. Leucht S, Pitschd-Walz G, Abraham D, Kisseling W. Efficacy and extrapyramidal side effects of the new antypsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 1998; 35: 51-68.
9. Kane J, Honigfeld G, Singer J, Meltzer H and Clozaril Collaboration Study Group. Clozapine for the treatment-resistant schizophrenic. Arch Gen psychiatry 1988; 45: 789-796.
10. Kahn RS. Atypische antipsychotica. Ned Tijdschr Geneesk 2000; 144: 1627-30.
11. Howanitz E, Pardo M, Smelson DA, Engelhart C, Eisenstein N, Losonczy MF. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry 1999; 60: 41-44.
12. Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G. International multisite double-blind trial of the atypical antipsychotics risperidone and clanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2003; 11: 638-647.
13. McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999; 60: 292-98.
14. Solomons K, Geiger O. Olanzapine use in the elderly: a retrospective analysis. Can J Psychiatry 2000; 45: 15-55.
15. Barak Y, Wittenberg N, Naor S, Weizman A. Clozapine in elderly psychiatric patients: tolerability, safety and efficacy. Comp Psychiatry; 40: 320-25.
16. Madhusoodanan S, Brecher M, Brenner R, Kasckow J, Kunik M, Negrón AE et al. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry 1999; 7: 132-38.
17. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double blind trial. J Clin Psychiatry 1999; 60: 107-15.
18. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PLJ, Eriksson S et al. A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946-55.
19. Street JS, Clark WS, Cannon KS, Cummings JL, Bymaster FP, Tamura RN et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. Arch Gen Psychiatry 2000; 57: 968-76.
20. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD et al. Olanzapine versus placebo in the treatment of psychosis wit hor without associated behavioral disturbances in patients with Alzheiemer's disease. Int J Geriatr Psycgiatry 2004; 19: 115-26.
21. Stoppe g, Brandt CA, Staedt JH. Behavioral problems associated with dementia; the role of newer antipsychotics. Drugs&Aging 1999; 14: 41-54.
22. Scharre DW, Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alz Disease Ass Disord 2002; 16: 128-30.
23. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001; 57: 2078-82.
24. Lemstra AW, Eikelenboom P, van Gool WA. The cholinergic deficiency syndrome and its therapeutic implications. Gerontol 2003; 49: 55-60.
25. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Enl J Med 1999; 340: 757-63.
26. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999; 353: 2041-42.
27. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine; comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55: 789-94.
28. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002; 52: 438-45.
29. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17: 1031-35.
30. Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 1997; 48: 1077-81.
31. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 201-11.
32. Reddy S, Factor SA, Molho ES, feustel PJ et al. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17: 676-81.
33. Fabbrini G, Barbanti P, Aurilia C. Tardive dyskinesias in the elderly. Int J Geriatr Psychiatry 2001; 16: S19-S23.
34. Jeste DV, Lacro JP, Bailey A, Rockwell e, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47: 716-19.
35. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003; 53: 1142-45.
36. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. N Engl J Med 1993; 329: 162-67.
37. van Melick EJM, Touw DJ, Haak HL. Agranulocytosis door clozapine: het belang van leukocytencontrole en het nut van bloedgroeifactoren. Ned Tijdschr Geneesk 1995; 139: 2437-40.
38. Naumann R, Felber W, Heilemann H, Reuster T. Olanzapine-induced agranulocytosis. Lancet 1999; 354: 566-67.
39. Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 1998; 59 (suppl 3): 38-43.
40. Garver DL. Review of quetiapine side effects. J Clin Psychiatry 2000; 61 (suppl 8): 31-33.
41. Taylor DM, McAskill R. Atypical antipsychotics and weight gain; a systematic review. Acta psychiatr Scand 2000; 101: 416-32.
42. Barak Y. No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. J Clin Psychiatry 2002; 63: 117-119.
43. Meyer JM. A retrospective comparison of weight, lipid and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63: 425-33.
44. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001; 16: 63-74.
45. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290-96.
46. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369-74.
47. Czekalla J, Kollack-Walker S, Beasley CM. Cardiac safety parameters of olanzapine; comparison with other atypical and typical antipsychotics. J Clin Psychiatry 2001; 62(suppl 2): 35-40.
48. Kang UG, Kwon JS, Ahn YM, Chung SJ, Ha JH, Koo YJ et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 2000; 61: 441-46.
49. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-5
50. Ananth J, Parameswaran S, Gunatilake S, Burgoune K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65(4): 464-70.